ArticleNature communications2025
Using COVID-19 pandemic perturbation to model RSV-hMPV interactions and potential implications under RSV interventions.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.PLoS computational biology · 2026Article
- The limitations of non-mechanistic methods for characterizing pathogen-pathogen interactions: A simulation study.PLoS computational biology · 2026Article
- Spatiotemporal Dynamics of Human Metapneumovirus and Potential Impact of Respiratory Syncytial Virus Interventions in the United States.medRxiv : the preprint server for health sciences · 2026Article
- Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.medRxiv : the preprint server for health sciences · 2026Article
- Avian Metapneumovirus: Virology, Epidemiology, and Insights from a Comparative Analysis with Human Metapneumovirus-A Review.Biomolecules · 2026Review
- Complex multiannual cycles ofProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Dynamic ensemble deep learning with multi-source data for robust influenza forecasting in Yangzhou.BMC public health · 2025Article
- Human Metapneumovirus: A Narrative Review on Emerging Strategies for Prevention and Treatment.Viruses · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are closely related pathogens responsible for a significant burden of acute respiratory infections. Interactions between RSV and hMPV have been hypothesized, but the mechanisms of interaction are largely unknown. Here, we use a mathematical model to quantify the likelihood of interactions from population-level surveillance data and investigate whether interactions could lead to increases in hMPV burden under RSV medical interventions, including active and passive immunization. In Scotland, Korea, and three regions of Canada, annual hMPV outbreaks lag RSV outbreaks by up to 18 weeks; two Canadian regions show patterns consistent with out-of-phase biennial outbreaks. Using a two-pathogen transmission model, we show that a negative effect of RSV infection on hMPV transmissibility can explain these dynamics. We use post-pandemic RSV-hMPV rebound dynamics as an out of sample test for our model, and the model with interactions better predicts this period than a model where the pathogens are assumed to be independent. Finally, our model suggests that hMPV peak timing and magnitude may change under RSV interventions. Our analysis provides a foundation for detecting possible RSV-hMPV interactions at the population level, although such a model oversimplifies important complexities about interaction mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.